Compounds that bind to phosphatidylinositol-4-kinase IotaIIbeta (RhoIota4KappaIotaIotaIotabeta) and inhibit the binding of RhoIota4KappaIotaIIbeta to its substrate and/or inhibit RhoIota4KappaIotaIotaIotabeta activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of RhoIota4KappaIotaIotaIotabeta activity, is also disclosed.
